Abstracts tagged "BAFF"

Abstract Number: 7 • 2017 Pediatric Rheumatology Symposium
Activation of Immature, Transitional B cells by Integrated BCR, TLR and TACI signals promotes systemic autoimmunity in high BAFF settings
Holly Jacobs, Samuel Du, Tanvi Arkatkar and Shaun Jackson, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: B cell activating factor of the TNF family (BAFF, also known as BLyS) promotes B cell survival and activation by binding distinct B cell…
Abstract Number: 2831 • 2016 ACR/ARHP Annual Meeting
Associations of BAFF and Anti-BAFF Autoantibodies with Disease Activity in Oriental Systemic Lupus Erythematosus
Hwee-Siew Howe¹, Bernard Thong², Kok Ooi Kong³, Hiok-Hee Chng², Tsui Yee Lian², Faith Chia², Karine Tay², Tang Ching Lau⁴, Weng Giap Law², Ee Tzun Koh⁵ and Bernard Pui Lam Leung^6,7, ¹Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, SINGAPORE, Singapore, ²Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, ., Singapore, ³Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore, ⁴Yong Loo Lin School of Medicine,, National University of Singapore, ., Singapore, ⁵Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, ., Singapore, ⁶Physiology, National University of Singapore, ., Singapore, ⁷Rheumatology, Allergy & Immunology, Tan Tock Seng Hospital, ., Singapore
Background/Purpose: B cell activating factor (BAFF) is implicated in the pathogenesis of systemic lupus erythematosus (SLE). A previous small scale study reported that endogenous neutralizing…
Abstract Number: 2873 • 2016 ACR/ARHP Annual Meeting
B-Cell activating Factor Genetic Variants in Systemic Lupus Erythematosus and Lupus Related Atherosclerosis
Evangelos Theodorou¹, Adrianos Nezos², Pinelopi Kostantopoulou³, Maria Tektonidou⁴, Michael Koutsilieris⁵ and Clio P. Mavragani⁵, ¹Rheumatology, 251 Hellenic (Greek) Air Force Hospital, Athens, Greece, ²Physiology, Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, ³Rheumatology Department, General Hospital of Athens "G.Gennimatas", Αthens, Greece, ⁴Laikon Hospital, Athens University Medical School, Athens, Greece, ⁵Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease with an increased atherosclerotic risk compared to healthy population, partially explained by traditional cardiovascular…
Abstract Number: 3034 • 2016 ACR/ARHP Annual Meeting
A Selective JAK1 Inhibitor, Filgotinib Suppresses Lymphocytic Infiltration in Salivary Gland of Non Obese Diabetic Mice Via Suppression of BAFF and Chemokine Production of Salivary Gland Epithelial Cells
Jennifer Lee¹, Seo Hwa Kim², Haneul Kim³, Seung-Ki Kwok⁴, Ji Hyeon Ju⁵ and Sung-Hwan Park⁵, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, ²Division of Rheumatology,, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ⁴[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Interferon(IFN) signatures are upregulated in patients with primary Sjogren’s syndrome (pSS) and interferons are considered to play a pathogenic role in pSS. Therefore, Janus…
Abstract Number: 3244 • 2016 ACR/ARHP Annual Meeting
Observations of Early and Late B Cell Alterations during Belimumab Treatment in Patients with Systemic Lupus Erythematosus Using Mass Cytometry (CyTOF)
Ioannis Parodis¹, Daniel Ramsköld¹, Petter Brodin², Agneta Zickert¹, Lakshmikanth Tadepally², Yang Chen², Jaromir Mikes², Adnane Achour², Iva Gunnarsson¹ and Vivianne Malmström¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Science for Life Laboratory, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Belimumab is a recombinant monoclonal antibody that inhibits soluble B lymphocyte stimulator (BLyS), also known as BAFF or TNFSF13B, and is approved for treating…
Abstract Number: 654 • 2016 ACR/ARHP Annual Meeting
The Level of B-Cell Active Cytokines and Soluble B-Cell Activating Factor/a Proliferation-Inducing Ligand Receptors in Patients with Primary Sjogren’s Syndrome
You Jung Ha¹, Jaehyung Hur¹, Sang Wan Chung¹, Eun Ha Kang², Yeong Wook Song^3,4 and Yun Jong Lee⁵, ¹Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, The Republic of, ³WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Medical Research Institute, WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Medical Research Institute, Seoul National University College of Medicine, Seoul, Korea, The Republic of, ⁴Department of Internal Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
Background/Purpose: Primary Sjögren`s syndrome (pSS) is an autoimmune diseases characterized by lymphocytic infiltration of exocrine glands and dysregulated proliferation and differentiation of B cells. Two…
Abstract Number: 742 • 2016 ACR/ARHP Annual Meeting
A Pivotal Phase III, Randomized, Placebo-Controlled Study of Belimumab in Patients with Systemic Lupus Erythematosus Located in China, Japan, and South Korea
Fengchun Zhang¹, Sang-Cheol Bae², Damon Bass³, Myron Chu³, Sally Egginton⁴, David Gordon³, David Roth³, Yoshiya Tanaka⁵ and Jie Zheng⁶, ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, The Republic of, ³GSK, Philadelphia, PA, ⁴GSK, Stevenage, United Kingdom, ⁵University of Occupational and Environmental Health, Kitakyushu, Japan, ⁶Ruijin Hospital affiliated to Shanghai Jiao Tong University, Shanghai, China
Background/Purpose: SLE is an autoimmune disease associated with elevated levels of B Lymphocyte Stimulator (BLyS). This study assessed the efficacy and safety of belimumab (BLyS-specific…
Abstract Number: 745 • 2016 ACR/ARHP Annual Meeting
Clinical and Laboratory Correlates of Response in a Phase 3 Clinical Trial of Belimumab or Placebo Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)
Ronald F. van Vollenhoven¹, William Stohl², Richard Furie³, Norma Lynn Fox⁴, James Groark⁵, Damon Bass⁵, Milena Kurtinecz⁵, Bonnie Pobiner⁶, William Eastman⁶, Tania Gonzalez-Rivera⁵ and David Gordon⁵, ¹Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴GSK, Potomac, MD, ⁵GSK, Philadelphia, PA, ⁶GSK, Research Triangle Park, NC
Background/Purpose: The SRI (SLE responder index) is a composite measure established as a primary endpoint in SLE clinical trials. However, it has been questioned whether…
Abstract Number: 756 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics and Exposure-Response Relationship of Belimumab Administered Subcutaneously to SLE Patients
Herbert Struemper¹, Mita Thapar², David Gordon³ and David Roth³, ¹Quantitative Clinical Development, PAREXEL, Durham, NC, ²ICON, Marlow, United Kingdom, ³GSK, Philadelphia, PA
Background/Purpose: Monthly (q4w) intravenously (IV) administered belimumab 10 mg/kg is approved for the treatment of adults with active, autoantibody-positive SLE receiving standard therapy. The present…
Abstract Number: 1081 • 2016 ACR/ARHP Annual Meeting
The CRL4CRBN E3 Ubiquitin Ligase Modulator CC-220 Inhibits BAFF-Mediated Plasmablast Differentiation and Immunoglobulin Secretion from Class Switched CD27+IgD- Memory and Lupus-Associated CD27-IgD- Double Negative B-Cells
Yumi Nakayama¹, Jolanta Kosek¹, Lori Capone², Peter H. Schafer³ and Garth Ringheim¹, ¹Inflammation and Immunology Translational Development, Celgene Corporation, Summit, NJ, ²Celgene Corporation, Summit, NJ, ³Department of Translational Development, Celgene Corporation, Summit, NJ
Background/Purpose: Changes in the ratio of circulating memory, naive, and double negative CD27-IgD- B cell subsets are associated with a higher disease activity index in…
Abstract Number: 1453 • 2016 ACR/ARHP Annual Meeting
Treatment of BAFF Transgenic Mice with Anti-TNF: Monoclonals Are Associated with a Higher Risk of Lymphoma Than Etanercept
Gaetane Nocturne^1,2, Bineta Ly³, Saida Boudaoud⁴, raphaèle seror^5,6, Carole Nicco⁷, Christiane Chereau⁷, Niloufar Kavian^7,8, Frederic Batteux^7,8, Fabienne Mackay⁹, Fabien Vincent⁹, Thierry Lazure¹⁰, Sophie Ferlicot¹⁰, Lev Stimmer¹¹, Roman Krzysiek¹⁰, Salima Hacein-Bey¹⁰ and Xavier Mariette^12,13, ¹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ²INSERM U1184, Université Paris Sud, Le Kremlin Bicêtre, France, ³INSERM U1184, Paris Sud University, Kremlin Bicetre, France, ⁴INSERM U1184, Paris Sud University, Le Kremlin Bicêtre, France, ⁵Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ⁶INSERM U1184, Paris Sud University, Le Kremlin Bicetre, France, ⁷Institut Cochin, Paris, France, ⁸Immunology, APHP Hopital Cochin, Paris, France, ⁹Monash university, Melbourne, Australia, ¹⁰APHP Hopitaux universitaires Paris sud, Le Kremlin Bicetre, France, ¹¹CEA - MIRCen, Fontenay aux Roses, France, ¹²Department of Rheumatology, APHP - Hopitaux universitaire Paris Sud, Le Kremlin Bicetre, France, ¹³INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France
Background/Purpose: Patients suffering from rheumatoid arthritis (RA) have an increased risk of lymphoma and disease activity is the main risk factor. The impact of treatment,…
Abstract Number: 1951 • 2016 ACR/ARHP Annual Meeting
Phenotypic and Functional Perturbations of Peripheral B and T Lymphocytes in Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Jonathan London^1,2,3, Nicolas Dumoitier¹, Jeremie Dion^1,4, Benjamin Chaigne^1,5, Sebastien Lofek¹, Pascal Cohen^2,3, Claire Le Jeunne³, Nadine Varin-Blank⁶, Loïc Guillevin^3,5, Benjamin Terrier^1,5,7, Luc Mouthon^1,3,5 and the French Vasculitis Study Group, ¹INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ²Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ⁴Internal medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁶UFR SMBH, INSERM, UMR978, Bobigny, France, ⁷Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are both anti-neutrophil cytoplasm antibodies (ANCA)-associated vasculitides (AAV), but differ in clinical presentation. Anti-myeloperoxydase (MPO)-ANCA were…
Abstract Number: 2110 • 2016 ACR/ARHP Annual Meeting
Synovial Fibroblasts Regulate B Cell Survival Via B Cell Activating Factor of the TNF Family (BAFF)
Torsten Lowin¹, Matthias Schneider² and Georg Pongratz³, ¹Rheumatology, University Hospital Duesseldorf, Duesseldorf, Germany, ²Rheumatology - Hiller Research Center Rheumatology, University Hospital Duesseldorf, Düsseldorf, Germany, ³Rheumatology - Hiller Research Center Rheumatology, University Hospital Duesseldorf, Duesseldorf, Germany
Background/Purpose: In rheumatoid arthritis (RA), synovial fibroblasts (SF) are one main contributor of joint destruction since they resist apoptosis and secrete pro-inflammatory cytokines and matrix…
Abstract Number: 1098 • 2015 ACR/ARHP Annual Meeting
Interleukin-1 Reciprocally Regulates Interferon-Gamma Induced B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) and Interleukin-6 in Human Synovial Fibroblasts
Georg Pongratz¹, Rainer Straub² and Torsten Lowin³, ¹Rheumatology - Hiller Research Center Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany, ²Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine, University Hospital Regensburg, Regensburg, Germany, ³Internal Medicine I, University Hospital Regensburg, Regensburg, Germany
Background/Purpose: B cell activating factor of the tumor necrosis factor family (BAFF) and interleukin-6 (IL-6) are cytokines important for the stimulation and survival of autoreactive…
Abstract Number: 1117 • 2015 ACR/ARHP Annual Meeting
The B Cell Survival Cytokine BAFF Promotes Systemic Lupus Erythematosus Via Activation of TACI, Not BAFF Receptor
Holly Jacobs¹, Christopher Thouvenel¹, Tanvi Arkatkar¹, Nicole Scharping¹, David Rawlings² and Shaun Jackson¹, ¹Seattle Children's Research Institute, Seattle, WA, ²Pediatrics/Immunology, Washington, Seattle, WA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by polyclonal B cell activation and production of class-switched antinuclear antibodies (ANA). Transgenic mice…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].